<DOC>
	<DOCNO>NCT02478866</DOCNO>
	<brief_summary>BPI-9016M novel , highly potent selective small-molecule inhibitor c-Met/Axl kinase . In preclinical study , demonstrate strong activity vitro vivo c-Met/Axl kinase downstream signal target , inhibited tumor cell growth . This first-in-human study conduct assess maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) , evaluate pharmacokinetics , safety preliminary anti-tumor activity BPI-9016M single dos multiple dos .</brief_summary>
	<brief_title>Safety Pharmacokinetics BPI-9016M Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This phase Ia study , first-in-human , open-label , dose-escalation study BPI-9016M administer orally daily ( QD ) patient locally advance metastatic solid tumors.The study design evaluate safety , tolerability , pharmacokinetics single dose multiple dos BPI-9016M . All patient follow adverse event study treatment 28 day last dose study drug . Subjects study permit continue therapy BPI-9016M well tolerate , tumor response stable disease see .</detailed_description>
	<criteria>Histologically cytologically confirm , locally advanced , metastatic solid tumor progress , fail respond , least one prior systemic therapy Evaluable measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST1.1 ) Life expectancy ≥3 month Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Adequate bone marrow , hepatic , renal function Patients child bear potential must agree take contraception study 90 day last day treatment Signed Informed Consent Form Prior treatment agent HGF/cMet inhibitor HGF/cMet antibody ( Including Crizotinib , Cabozantinib , Volitinib etc . ) Any anticancer therapy , include chemotherapy , hormonal therapy , biologic therapy radiotherapy within 4 week prior initiation study treatment History organ transplant ; surgery severe injury within 4 week Adverse event prior anticancer therapy resolve Grade ≤ 2 , except alopecia Any evidence severe uncontrolled systemic disease , include CTCAE 3 high active infection , unstable angina pectoris , congestive cardiac failure severe liver/renal metabolic disease Pregnant ( positive pregnancy test ) lactate woman Inability take oral medication , prior surgical procedure affect absorption , active peptic ulcer disease Brain/meninges metastases unless asymptomatic , stable require steroid maintenance Active infection include hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) Inability comply study followup procedure Any disease , metabolic dysfunction , physical examination finding , clinical laboratory finding , investigator 's opinion , give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render patient high risk treatment complication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>